A Novel Combination Therapy Tβ4/VIP Protects against Hyperglycemia-Induced Changes in Human Corneal Epithelial Cells.
Quick Facts
What This Study Found
Tβ4/VIP treatment significantly improved barrier function and cell migration in high glucose conditions.
Key Numbers
How They Did This
The study used electric cell-substrate impedance sensing (ECIS) to monitor barrier function and wound healing in human corneal epithelial cells exposed to normal and high glucose levels with and without Tβ4/VIP treatment.
Why This Research Matters
This research offers a potential new treatment for diabetic patients suffering from corneal complications, which currently have limited options. Improving corneal health can enhance overall quality of life for these individuals.
What This Study Doesn't Tell Us
The study was conducted in vitro, so results may not fully translate to human patients. Further research is needed to confirm efficacy in clinical settings.
Trust & Context
- Original Title:
- A Novel Combination Therapy Tβ4/VIP Protects against Hyperglycemia-Induced Changes in Human Corneal Epithelial Cells.
- Published In:
- Biosensors, 13(11) (2023)
- Authors:
- Ebrahim, Abdul Shukkur(2), Carion, Thomas W(2), Ebrahim, Thanzeela, Win, Jeff, Kani, Hussein, Wang, Yuxin, Stambersky, Ashten, Ibrahim, Ahmed S, Sosne, Gabriel, Berger, Elizabeth A
- Database ID:
- RPEP-06855
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06855APA
Ebrahim, Abdul Shukkur; Carion, Thomas W; Ebrahim, Thanzeela; Win, Jeff; Kani, Hussein; Wang, Yuxin; Stambersky, Ashten; Ibrahim, Ahmed S; Sosne, Gabriel; Berger, Elizabeth A. (2023). A Novel Combination Therapy Tβ4/VIP Protects against Hyperglycemia-Induced Changes in Human Corneal Epithelial Cells.. Biosensors, 13(11). https://doi.org/10.3390/bios13110974
MLA
Ebrahim, Abdul Shukkur, et al. "A Novel Combination Therapy Tβ4/VIP Protects against Hyperglycemia-Induced Changes in Human Corneal Epithelial Cells.." Biosensors, 2023. https://doi.org/10.3390/bios13110974
RethinkPeptides
RethinkPeptides Research Database. "A Novel Combination Therapy Tβ4/VIP Protects against Hypergl..." RPEP-06855. Retrieved from https://rethinkpeptides.com/research/ebrahim-2023-a-novel-combination-therapy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.